News

NicOx and Merck said that the approach may be used to develop new classes of NO-donating new molecular entities (NMEs), designed to offer a different mechanism for controlling

The antibody clones include the reagents used for studying macrophage subsets in rats, the ‘ED series’ of antibodies. The agreementis expected to strengthen AbD Serotec’s position as primary

With the addition of the ELSD-1080, Biotage provides a flash purification solution for nearly every compound type including semi-volatile UV transparent as well as UV absorbing compounds. The

Geron said that the revenues for the second quarter and year to date period of 2010 reflect funding from collaboration agreements and royalty and license fee revenues under

Acadia Pharma is expected to recruit approximately 200 patients at clinical sites located in North America. Patients in the trial will be randomised on a one-to-one basis to

Bio-Path stated that the Phase I clinical trial is a dose-escalating study to determine the safety and tolerance of escalating doses of L-Grb-2. The pharmacokinetics of L-Grb-2 in

Versartis said that VRS-317, a once monthly form of human growth hormone for the treatment of children and adults with growth hormone deficiency. Earlier, SynCo Bio Partners (SynCo)

Most recently, Dr Miller has served as a chief medical officer of PTC Therapeutics and led the strategic design and implementation of development activities for the company’s clinical-stage

Shionogi said that Cuvposa is a competitive inhibitor of acetylcholine receptors that are located on certain peripheral tissues, including salivary glands. Cuvposa indirectly reduces the rate of salivation